YU49995A - POLYNUCLEOTIDE VACCINE FOR HERPES VIRUS - Google Patents

POLYNUCLEOTIDE VACCINE FOR HERPES VIRUS

Info

Publication number
YU49995A
YU49995A YU49995A YU49995A YU49995A YU 49995 A YU49995 A YU 49995A YU 49995 A YU49995 A YU 49995A YU 49995 A YU49995 A YU 49995A YU 49995 A YU49995 A YU 49995A
Authority
YU
Yugoslavia
Prior art keywords
hsv
pnv
immunization
animals
herpes virus
Prior art date
Application number
YU49995A
Other languages
Serbo-Croatian (sh)
Inventor
M.E. Amstrong
R.D. Keys
M.A. Lewis
M.A. Liu
W.L. Mc CLEMENTS
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of YU49995A publication Critical patent/YU49995A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

POLINUKLEOTIDNA VAKCINA ZA VIRUS HERPESA - Geni koji kodiraju proteine herpes simpleks virusa tipa 2 (HSV-2) se kloniraju u eukariotične ekspresione vaktore da bi ekspresionisali kodirane proteine in vivo i mišićne delije sisara. Životinje se imuniziraju injekcijom ovih DNK konstrukcija, nazvanih polinukleotidne vakcine ili PNV, u njihove mi'Side. U DNK titraciji nadeno je da jedna imunizacija od. 0.5 "F128M".m"F255D".g fledne PNV daje 90% serokonverzije za deset nedelja posle imunizacije. Imuni antiserumi neutralist i HSV-2 i HSV-1 u ćelijskoj kulturi. Kad se životinje izazovu sa HSV-2 postignuta je značajna (p .001) zaštita od letalne infekcije posle PNV vakcinacije.HERPES VIRUS POLYNUCLEOTIDE VACCINE - Genes encoding herpes simplex virus type 2 (HSV-2) proteins are cloned into eukaryotic expression vactors to express encoded proteins in vivo and mammalian muscle cells. Animals are immunized by injecting these DNA constructs, called polynucleotide vaccines or PNVs, into their muscles. In DNA titration it was found that one immunization of. 0.5 "F128M" .m "F255D" .g fledne PNV gives 90% seroconversion in ten weeks after immunization. Immune antiserums neutralize both HSV-2 and HSV-1 in cell culture. When animals were challenged with HSV-2, significant (p .001) protection against lethal infection was achieved after PNV vaccination.

YU49995A 1994-07-22 1995-07-21 POLYNUCLEOTIDE VACCINE FOR HERPES VIRUS YU49995A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27945994A 1994-07-22 1994-07-22

Publications (1)

Publication Number Publication Date
YU49995A true YU49995A (en) 1998-05-15

Family

ID=23069059

Family Applications (1)

Application Number Title Priority Date Filing Date
YU49995A YU49995A (en) 1994-07-22 1995-07-21 POLYNUCLEOTIDE VACCINE FOR HERPES VIRUS

Country Status (10)

Country Link
EP (1) EP0772680A1 (en)
JP (1) JPH10503649A (en)
AU (1) AU708460B2 (en)
CA (1) CA2195099A1 (en)
CO (1) CO4410257A1 (en)
HR (1) HRP950412A2 (en)
IL (1) IL114576A0 (en)
WO (1) WO1996003510A1 (en)
YU (1) YU49995A (en)
ZA (1) ZA956106B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849719A (en) * 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US7094767B2 (en) 1994-07-22 2006-08-22 Merck & Co., Inc. Polynucleotide herpes virus vaccine
AU738835B2 (en) * 1994-07-22 2001-09-27 Merck & Co., Inc. A polynucleotide herpes virus vaccine
CA2267645A1 (en) * 1996-10-01 1998-04-09 Merck & Co., Inc. A polynucleotide herpes virus vaccine
JP2001503258A (en) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド Gene expression and delivery systems and applications
CA2268365A1 (en) * 1996-10-18 1998-04-30 Jeff Nordstrom Il-12 gene expression and delivery systems and uses
GB9720633D0 (en) * 1997-09-29 1997-11-26 Univ Bristol BHV-2 vector
US6488936B1 (en) * 1998-02-12 2002-12-03 Wyeth Immunogenic composition of interleukin-12 (IL-12), alum, herpes simplex viral (HSV) antigen, and method thereof
US6867000B2 (en) * 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
US9012349B1 (en) 2013-11-01 2015-04-21 Ut-Battelle Llc Method of synthesizing bulk transition metal carbide, nitride and phosphide catalysts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612983B2 (en) * 1986-08-01 1991-07-25 Australian National University, The Recombinant vaccine
DE69034078T2 (en) * 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression of exogenous polynucleotide sequences in vertebrates
DE69019609T2 (en) * 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteins and their production.

Also Published As

Publication number Publication date
WO1996003510A1 (en) 1996-02-08
CA2195099A1 (en) 1996-02-08
HRP950412A2 (en) 1997-10-31
ZA956106B (en) 1996-04-10
AU3101295A (en) 1996-02-22
CO4410257A1 (en) 1997-01-09
EP0772680A1 (en) 1997-05-14
AU708460B2 (en) 1999-08-05
IL114576A0 (en) 1995-11-27
JPH10503649A (en) 1998-04-07

Similar Documents

Publication Publication Date Title
AU734442B2 (en) Polynucleotide vaccine formula in particular against bovine respiratory pathology
ATE85622T1 (en) CHIMERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SEGMENTS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS.
CN110269932A (en) African swine fever virus vaccine and application thereof
ATE219948T1 (en) RECOMBINANT VACCINES THAT CONTAIN IMMUNOGENE ATTENUATE RPOS-POSITIVE PHENTOTYPE BACTERIA
DK0500917T3 (en) Vaccines and methods based on recombinant herpes simplex viruses.
BR9205771A (en) Recombinant virus vector and process for its manufacture
EP0400958A3 (en) Live vaccines
YU49995A (en) POLYNUCLEOTIDE VACCINE FOR HERPES VIRUS
Andrew et al. Protection of pigs against classical swine fever with DNA-delivered gp55
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
EP0192902A2 (en) DNA sequences from Varicella-zoster virus, vectors and hosts containing them, the corresponding polypeptides and the compositions containing them
ATE173166T1 (en) NEW BACTERIAL VACCINES USING VACCINE STRAINS OF PATHOGENIC BACTERIA
HK51597A (en) Vaccines for human respiratory virus
EP0294469A4 (en) Vaccines and diagnostic assays for haemophilus influenzae.
ZA918876B (en) Avirulent microbes and uses therefor:salmonella typhi
DE69030099T2 (en) METHOD FOR PRODUCING VACCINE OR TOXOID
ES8505253A1 (en) Production of herpes simplex viral proteins.
DE69332264D1 (en) MUTANTS OF THE INFECTIOUS CATTLE RHINOTRACHEITIS VIRUS AND VACCINE
ES2322236T3 (en) MUTANTS OF THE GM-NEGATIVE EHV.
Castrucci et al. Immunization against bovine herpesvirus-1 infection. Preliminary tests in calves with a DNA vaccine
Wang et al. Construction, identification, and immunogenic assessments of an HSV-1 mutant vaccine with a UL18 deletion
GB9404577D0 (en) Vaccine compositions
CN102772793A (en) Brucella deoxyribonucleic acid (DNA) vaccine as well as construction method and application thereof
Amann et al. High-level production in Escherichia coli of hybrid proteins expressing parts of coding sequences of HSV glycoproteins.
Senthilnathan et al. Multivalent DNA vaccine expressing the glycoproteins and tegument protein of infectious laryngotracheitis virus elicits robust humoral and cellular immune response in chickens